Pancreatic Cancer Pill Daraxonrasib Gets FDA Breakthrough Status for Untreated Metastatic Disease When Paired with Standard Chemotherapy
4 Articles
4 Articles
Daraxonrasib extends survival in metastatic pancreatic cancer
1. Daraxonrasib is the first-in-class RAS inhibitor approved for metastatic pancreatic adenocarcinoma, addressing a molecular pathway that drives most pancreatic cancers but has historically been difficult to target pharmacologically. 2. In the randomized RASolute 302 trial, daraxonrasib extended median overall survival from 6.7 to 13.2 months and median progression-free survival from 3.6 to 7.2 months […] The post Daraxonrasib extends survival …
St. Charles Offers Groundbreaking Pancreatic Cancer Medication
(La Pine resident John Johnson is one of the local patients who received early access through St. Charles Cancer Institute to a medication for pancreatic cancer that has been shown to double life expectancy. The medication, daraxonrasib, was approved on August 26 by the FDA | Photo courtesy of St. Charles Health System) Patients at [...]
In the U.S., it's clear to the famous Daraxonrasib. In phase 3 trials, the median survival has increased from 6.7 to 13.2 months. An important result for one of the most difficult cancers to treat.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
